Photo taken from: Yüksel Ürün/X
Dec 19, 2023, 18:52
Yüksel Ürün: The final analysis of the IMvigor130
Yüksel Ürün, Professor at the Department of Medical Oncology, Ankara University School of Medicine, recently posted on X/Twitter:
“The final analysis of the IMvigor130:
- Atezolizumab didn’t significantly improve overall survival compared to chemotherapy
- It may still be an effective alternative, especially for patients with high PD-L1 expression who are ineligible for cisplatin.”
For details click here.
Source: Yüksel Ürün/X